GMP Surges for Symbiotec Pharmalab IPO as CDMO Stock Eyes 41% Listing Gain

GMP Surges for Symbiotec Pharmalab IPO as CDMO Stock Eyes 41% Listing Gain​

The Initial Public Offering (IPO) of Madhya Pradesh-based contract development and manufacturing organization (CDMO), Symbiotec Pharmalab, opened today with an initial subscription rate of 12 percent as of 11:00 am on August 24, according to NSE data. The IPO is for a total of Rs 1,757 crore and was available across various investor categories.

The issue sought bids from the public against 131,24,929 shares, with retail investors subscribing at 17 percent and Non-Institutional Investor (NII) category registering 15 percent subscription. The price band for the stock has been set between Rs 938 and Rs 988 per equity share.

Grey Market Premium Signals Strong Listing Potential​

In the grey market, Symbiotec Pharmalab shares are commanding a strong premium (GMP). According to InvestorGain data, the GMP stands at Rs 409. This indicates that if the stock lists at the upper end of the IPO price band (Rs 988), there is an estimated listing price of Rs 1,397.

This potential translates to a significant listing gain of approximately 41.4 percent. GMP serves as an unofficial market indicator and does not guarantee the final actual listing price or future returns.

Anchor Book Sees Major Institutional Interest​

Ahead of the public issue, the company successfully raised Rs 526.2 crore through its anchor book allotment. A total of 53.25 lakh equity shares were allotted to 34 institutional anchor investors at Rs 988 apiece.

Key anchors participating included Citigroup Global Markets, BNP Paribas, Singularity AMC, Susquehanna Pacific, and TIMF Holdings. Furthermore, eleven domestic mutual funds through 19 schemes participated. These funds are managed by ICICI Prudential AMC, HDFC Mutual Fund, Motilal Oswal AMC, Mirae Asset, Tata Mutual Fund, Edelweiss, Groww Mutual Fund, and ITI Mutual Fund.

Insurance companies also showed strong confidence in the anchor book. Tata AIA Life, Bajaj Life, and Bharti AXA Life participated, acquiring 4.25 lakh shares worth around Rs 42 crore.

IPO Structure Details Fresh Issue and Offer for Sale​

The IPO structure comprises a fresh issue of Rs 150 crore and an Offer For Sale (OFS) component amounting to Rs 1,607 crore. Proceeds from the OFS will be transferred directly to the respective selling shareholders.

Promoter Satwani Holdings, along with selling shareholders Rosewood Investments and Motilal Oswal, are offering their shares through the OFS. Of the fresh issue proceeds, Rs 112.5 crore is designated for debt repayment, while the balance will be utilized for general corporate purposes.

Company Profile and Operational Expansion Focus​

Symbiotec Pharmalab operates as a CDMO (Contract Development and Manufacturing Organization), serving specialty pharmaceutical and nutraceutical companies globally. Its core operations span three critical platforms: organic chemistry, biotechnology, and complex injectables.

As of March 2026, the company possessed two operational industrial-scale API manufacturing facilities. These facilities have a maximum chemical synthesis capacity of 584.67 metric tonnes (MT) and a fermentation capacity of 300 kilolitres (KL). The company is actively expanding its biologics manufacturing capabilities.

The business has also commissioned two additional manufacturing facilities in Ujjain and Mhow within Madhya Pradesh. Symbiotec Pharmalab has proposed a dedicated 14 KL fermentation facility at Ujjain to bolster its capacity.

Financial Outlook Points to Growth Trajectory​

Financially, the company projects continued growth. Profit is expected to grow at a compound annual growth rate (CAGR) of 4.81 percent between FY24 and FY26, reaching Rs 109.9 crore in FY26. Revenue growth during the same period is projected at a CAGR of 10.16 percent, targeting Rs 869.1 crore in FY26.

The book-running lead managers for this issue include JM Financial, Avendus Capital, Motilal Oswal Investment Advisors, and Nomura Financial Advisory and Securities (India). The shares are scheduled to be listed on the BSE and NSE on September 1, contingent upon the successful completion of the IPO process.